Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compositions, devices and methods for treating obsessive-compulsive disorder

A composition, obsessive-compulsive disorder technology, applied in the directions of drug combination, drug delivery, pharmaceutical formulation, etc., can solve the problem of bacterial superinfection difficult to be found and so on

Inactive Publication Date: 2019-09-27
CENT FOR DIGESTIVE DISEASES PTY LTD
View PDF18 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0002] Some conditions are clinically characterized by superinfected stools, but bacterial superinfection is difficult to detect
These pose a medical challenge to treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions, devices and methods for treating obsessive-compulsive disorder
  • Compositions, devices and methods for treating obsessive-compulsive disorder
  • Compositions, devices and methods for treating obsessive-compulsive disorder

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0196] A 16-year-old female patient with OCD, after years of compulsive handwashing and household cleaning, and exhibiting the behavior of putting knives and forks together in a specific symmetrical order, was treated with rifaximin 500mg bd and tinidazole 250mg Combination therapy for bd. Rifaximin dose was increased from 500mg bd to 500mg tds, and tinidazole was also increased to 250mg tds after 2 weeks. Over the next 6 months, the patient's compulsive handwashing, household cleaning, and obsession with knife and fork placement gradually decreased, eventually stopping completely at around 7-8 months. The dose of tinidazole was then increased to 500 mg twice daily, and the patient remained free of the aforementioned OCD symptoms during the subsequent 7-month follow-up.

Embodiment 2

[0198] A 22-year-old man with degenerative ASD also developed associated OCD. OCD is characterized by feeling compelled to put his hands together, as if praying multiple times a day. He will also hoard and stash clothing and other items such as cards. When starting with rifaximin 500mg tds with vancomycin 250mg tds the patient's vocabulary was only 20 or 30 words and later metronidazole 200mg bd was added. After 7 months of treatment, the condition began to improve. Over the next 3 months (months 8-10), the patient's OCD activity gradually decreased and was rarely seen at month 10. One year after starting treatment, the patient showed no further evidence of OCD and his vocabulary had increased to approximately 50 words as assessed by a speech-language pathologist.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for treating, ameliorating, reversing and / or preventing an obsessive-compulsive disorder (OCD) via the administration of a formulation, a pharmaceutical preparation or a pharmaceutical composition comprising or consisting of: (a) a rifaximin (optionally a XIFAXAN, XIFAXANTA or NORMIXT), an extended intestinal release (EIR) rifaximin, a rifamycin derivative, a rifampicin (or rifampin) (optionally RIFADIN), a rifabutin (optionally MYCOBUTIN), a rifapentine (optionally PRIFTIN), a rifalazil, a bicozamycin, a pyrido-imidazo rifamycin, or a mixture or combination thereof, or (b) a rifaximin, a polymorphic form of a rifaximin, or rifaximin equivalent thereof (optionally a XIFAXAN, XIFAXANTA or NORMIX) and at least one additional antimicrobial or antibiotic agent.

Description

technical field [0001] The present invention relates generally to medicine and gastroenterology, pharmacology and microbiology. In alternative embodiments, there is provided an obsessive-compulsive disorder (OCD) (e.g. , a pharmaceutical composition and method for degenerative autism). In alternative embodiments, these pharmaceutical compositions and methods are administered and administered to children in need thereof. In alternative embodiments, the pharmaceutical compositions and methods are formulated, formulated and administered as solid, liquid or aerosol doses or formulations. In alternative embodiments, the pharmaceutical composition comprises rifaximin as the sole antibiotic, or rifaximin and other antimicrobial or antibiotic agents, such as vancomycin, metronidazole, tinidazole, secnidazole, or combination. As a variety of molecular forms of rifaximin exist, all are useful and used in the methods and compositions provided herein. Background technique [0002] ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/437A61K31/496A61K31/454A61K31/495A61P25/00
CPCA61P25/00A61K31/437A61K31/4164A61K38/14A61K2300/00A61K31/4439A61K9/0056
Inventor 托马斯·朱利叶斯·波洛迪
Owner CENT FOR DIGESTIVE DISEASES PTY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com